EC approves PADCEV and KEYTRUDA combo for advanced urothelial cancer treatment
Astellas Pharma Inc. has announced a significant milestone in cancer treatment with the European Commission (EC's) approval of PADCEV (enfortumab vedotin) combined with KEYTRUDA (pembrolizumab). ... Read More
Breakthrough in cancer treatment: China approves PADCEV for advanced urothelial cancer
China's National Medical Products Administration (NMPA) has granted approval for PADCEV (enfortumab vedotin) to treat locally advanced or metastatic urothelial cancer (la/mUC) in adult patients. ... Read More
Japan’s MHLW grants priority review for PADCEV and KEYTRUDA combo in urothelial cancer
In a significant development in the fight against urothelial cancer, Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has awarded ... Read More
Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy
A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More
Phase 3 EV-302 clinical trial : Seagen, Astellas reveal promising for PADCEV and KEYTRUDA combo
Seagen Inc. and Astellas Pharma Inc. have announced encouraging results from the Phase 3 EV-302 clinical trial, presenting PADCEV in combination with KEYTRUDA versus chemotherapy. ... Read More